Aclaris Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Aclaris Therapeutics CEO'su Neal Walker, Jul2012 tarihinde atandı, in görev süresi 12.33 yıldır. şirketin hisselerinin 1.93% doğrudan sahiptir ve bu hisselerin değeri $ 2.82M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 10.5 yıldır.

Anahtar bilgiler

Neal Walker

İcra Kurulu Başkanı

US$73.5k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	12.3yrs
CEO sahipliği	1.9%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	10.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Neal Walker'un ücretlendirmesi Aclaris Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$37m
Jun 30 2024	n/a	n/a	-US$59m
Mar 31 2024	n/a	n/a	-US$77m
Dec 31 2023	US$74k	n/a	-US$88m
Sep 30 2023	n/a	n/a	-US$115m
Jun 30 2023	n/a	n/a	-US$105m
Mar 31 2023	n/a	n/a	-US$96m
Dec 31 2022	US$6m	US$590k	-US$87m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$83m
Mar 31 2022	n/a	n/a	-US$81m
Dec 31 2021	US$7m	US$567k	-US$91m
Sep 30 2021	n/a	n/a	-US$82m
Jun 30 2021	n/a	n/a	-US$71m
Mar 31 2021	n/a	n/a	-US$65m
Dec 31 2020	US$2m	US$424k	-US$51m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$69m
Mar 31 2020	n/a	n/a	-US$102m
Dec 31 2019	US$3m	US$500k	-US$114m
Sep 30 2019	n/a	n/a	-US$118m
Jun 30 2019	n/a	n/a	-US$115m
Mar 31 2019	n/a	n/a	-US$79m
Dec 31 2018	US$4m	US$550k	-US$82m
Sep 30 2018	n/a	n/a	-US$81m
Jun 30 2018	n/a	n/a	-US$79m
Mar 31 2018	n/a	n/a	-US$86m
Dec 31 2017	US$810k	US$510k	-US$50m

Tazminat ve Piyasa: Neal 'nin toplam tazminatı ($USD 73.50K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 356.13K ).

Tazminat ve Kazançlar: Neal 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Neal Walker (54 yo)

12.3yrs

Görev süresi

US$73,500

Tazminat

Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Neal Walker	Co-Founder	12.3yrs	US$73.50k	1.93% $ 2.8m
Kevin Balthaser	Chief Financial Officer	1.8yrs	US$2.34m	0.035% $ 50.6k
Joseph Monahan	Chief Scientific Officer	3.8yrs	US$2.26m	0.26% $ 383.3k
James Loerop	Chief Business Officer	2.8yrs	US$2.33m	0.048% $ 69.7k
Matthew Rothman	General Counsel & Corporate Secretary	2.4yrs	Veri yok	Veri yok
Jon Jacobsen	Senior Vice President of Chemistry	no data	Veri yok	Veri yok
Steve Tucker	Senior Vice President of Project Leadership	less than a year	Veri yok	Veri yok
Ajay Aggarwal	Senior Vice President of Clinical Development	less than a year	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: 0H8T 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Neal Walker	Co-Founder	12.3yrs	US$73.50k	1.93% $ 2.8m
Vincent Milano	Independent Director	4.8yrs	US$180.38k	0.018% $ 25.7k
Mark Bradshaw	Member of Advisory Board	no data	Veri yok	Veri yok
James Leyden	Member of Advisory Board	no data	Veri yok	Veri yok
Klaus Theobald	Member of Advisory Board	no data	Veri yok	Veri yok
Anand Mehra	Independent Director	10.2yrs	US$194.38k	0.061% $ 88.9k
Pearl Grimes	Member of Advisory Board	no data	Veri yok	Veri yok
Guy Webster	Member of Advisory Board	no data	Veri yok	Veri yok
Christopher Molineaux	Lead Independent Director	10.8yrs	US$206.88k	0.074% $ 109.0k
Kenneth Beer	Member of Advisory Board	no data	Veri yok	Veri yok
Leslie Baumann	Member of Advisory Board	no data	Veri yok	Veri yok
Andrew Ondo	Member of Advisory Board	no data	Veri yok	Veri yok

10.5yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0H8T 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.5 yıldır).

Aclaris Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Douglas Manion Steps Down as President and Member of the Board of Directors

Chief Financial Officer recently bought US$75k worth of stock

Chief Business Officer recently bought US$100k worth of stock

Recent updates

Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.42 loss in 2Q 2023)

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000 Growth Index

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Aclaris Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Full year 2023 earnings released: US$1.27 loss per share (vs US$1.33 loss in FY 2022)

Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Douglas Manion Steps Down as President and Member of the Board of Directors

Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc. Announces Top-Line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

New minor risk - Market cap size

Third quarter 2023 earnings released: US$0.41 loss per share (vs US$0.30 loss in 3Q 2022)

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Chief Financial Officer recently bought US$75k worth of stock

Chief Business Officer recently bought US$100k worth of stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.31 loss in 1Q 2022)

Co-Founder & Chairman recently sold US$510k worth of stock

Full year 2022 earnings released: US$1.33 loss per share (vs US$1.60 loss in FY 2021)

Chief Business Officer recently sold US$59k worth of stock

Aclaris Therapeutics, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2021)

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Executive Changes

Aclaris Therapeutics, Inc. Appoints Gail Cawkwell as Chief Medical Officer

Aclaris Therapeutics, Inc. Appoints Ian Anderson as Executive Vice President, Translational Research & Development

First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.57 loss in 1Q 2021)

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder recently sold US$896k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Aclaris Therapeutics, Inc. Names James Loerop as Chief Business Officer, Effective January 31, 2022

Aclaris Therapeutics Provides R&D Update

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.25 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.28 loss in 2Q 2020)

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Microcap Value Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000009 million.

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000009 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from Phase 2A Trial of ATI-1777

Co-Founder recently sold US$258k worth of stock

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.37 loss in 1Q 2020)

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

Full year 2020 earnings released: US$1.20 loss per share (vs US$2.75 loss in FY 2019)

Revenue beats expectations

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Dynamic Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $95.964995 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from 12-Week Phase 2A Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri